PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515388
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515388
Population Screening Market size was valued at USD 26,134.23 Million in 2023, expanding at a CAGR of 5.4% from 2024 to 2032.
Population screening is a public health strategy aimed at detecting disease or risk factors in a specific group of people who do not yet have symptoms. It involves systematically testing a large, defined population to identify individuals at higher risk of developing a particular condition. The goal is to enable early intervention, thereby improving health outcomes and reducing the burden of disease. Common examples include screenings for cancer, cardiovascular diseases, and genetic disorders. By identifying and managing diseases at an early stage, population screening can help lower treatment costs, enhance quality of life, and increase survival rates.
Population Screening Market- Market Dynamics
The increasing prevalence of chronic and non-communicable diseases propels market demand
Chronic and non-communicable diseases are becoming more widespread, which is creating a larger market for screening products. This is because both doctors and patients are looking for ways to identify these diseases early. Early detection can significantly reduce treatment costs, as later stages of these diseases often require more expensive interventions. The COVID-19 pandemic has even provided a boost to the population screening market. For example, Hayatt Med-Tech created the Hayatt Thermox-D in June 2021. This fully automated device can screen for multiple COVID-19 parameters and identify potential infections within 12 seconds. Additionally, it disinfects itself after each use. Furthermore, the development of new analytical technologies is expected to accelerate market growth. Looking specifically at cancer, its rising prevalence is a major driver for this market. The World Health Organization (WHO) reports that cancer is the world's second leading cause of death. In 2020 alone, there were 19.3 million fresh cancer cases diagnosed, with 9.96 million deaths. The International Agency for Research on Cancer (IARC) predicts these numbers to climb even higher, estimating 21.9 million new cases by 2025 and a staggering 24.6 million by 2030. This significant increase in cancer diagnoses is expected to push governments towards launching new cancer screening programs, further expanding the population screening market.
Population Screening Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.4% over the forecast period (2024-2032)
Based on Product Type segmentation, hardware equipment (instruments, kits, chips)l was predicted to show maximum market share in the year 2023
Based on Gender segmentation,= Female was the leading type in 2023
Based on Age segmentation, 65+ was the leading type in 2023
Based on Business segmentation, the hospital was the leading type in 2023
Based on Pricing Type segmentation, Mass was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Population Screening Market is segmented based on Product Type, Gender, Age, Pricing Type, Business and Region.
The market is divided into three categories based on Product Type: Hardware Equipment (Instrument, Kits, Chips), Testing / Lab (Services) and Analytics / Interpretation (Personalization And Interpretation). The hardware equipment type (instruments, kits, chips) segment held the largest revenue share in 2023. This growth can be attributed to the approval of equipment and novel test kits for the population screening of more diseases. For instance, in July 2022, Fujifilm Corporation inaugurated two new cancer screening facilities in India, which increased the demand for hardware and equipment for laboratory setups, driving the market. Additionally, in March 2021, Indigital Technologies launched Kribado, a handheld screening device, for risk stratification and NGS behavior settings devices for healthcare companies and practitioners. The increasing availability of such machines in clinics and hospitals is expected to boost the adoption of related procedures for early risk identification, helping ease the overall financial burden on healthcare systems.
The market is divided into three categories based on Business: Hospitals, Research Institutes, and Diagnostic Labs. The hospital segment accounted for the largest revenue share in 2023. Hospitals have experts who assist patients in selecting appropriate population screening tests. Market growth is driven by the increasing prevalence of chronic diseases, the availability of multiple testing options, and the launch of novel tests for more effective patient screening. For example, in July 2022, the Tamil Nadu Government Multi-Super Specialty Hospital (TNGMSSH) encouraged primary health centers in Greater Chennai Corporation to refer more women for anomaly screening. The hospital offers tests such as comprehensive blood tests, genetic biomarker testing, and ultrasound scans at USD 12.30 through its advanced master health checkup center package.
Population Screening Market- Geographical Insights
The geographic distribution of this market covers North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Countries within these regions broadly define further market segments. North America is poised to dominate the market, accounting for a significant revenue share in 2023. This growth is mainly attributed to preventive measures undertaken by governments to stop disease progression. In North America, the U.S. and Canada are major markets for population screening due to high awareness about the benefits of screening among patients and physicians. Tuberculosis (TB) prevention is a significant factor boosting the screening rate in the United States. Also, in 2019, the CDC and (NTCA) National Tuberculosis Controllers Association updated their recommendations for TB screening, testing, and treatment of healthcare personnel. Consequently, government initiatives to increase early disease diagnosis and treatment screenings are expected to drive market growth.
In the Population Screening Market, major players maintain dominance through strategic partnerships, frequent product launches, and technological advancements. Collaborations with healthcare institutions and research organizations enable access to extensive datasets, facilitating the development of comprehensive screening programs. Continuous innovation through product launches ensures offerings align with emerging healthcare needs, while R&D investments drive the exploration of new screening methodologies and technologies. Strategic acquisitions bolster companies' capabilities, enhancing their market position. Key players in the market are focusing on fostering new and existing partnerships, entering new territories, and strategic collaborations in upcoming and economically viable regions.
In April 2022, Quest Diagnostics partnered with (IRIS) Intelligent Retinal Imaging Systems to provide diabetic retinopathy testing services through its patient service centers in the United States. This partnership is expected to have a positive impact on the market.
GLOBAL POPULATION SCREENING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Quest Diagnostics
Illumina, Inc.
ARUP Laboratories
Novogene Co., Ltd.
LGC Limited
Gene by Gene, Ltd.
Others